Phase II trial of interferon-α in locally recurrent or metastatic squamous cell carcinoma of the head and neck: Immunological and clinical correlates

Journal of Immunotherapy

Volumn 19, Issue 6, 1996, Pages 433-442

  Vlock, Daniel R ^a   Andersen, Janet ^a   Kalish, Leslie A ^a   Johnson, Jonas T ^b   Kirkwood, John M ^a   Whiteside, Theresa ^c   Herberman, Ronald B ^a   Adams, George S ^c   Oken, Martin M ^c   Haselow, Robert E ^d  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Head and neck cancer; Interferon

Indexed keywords

ALPHA2B INTERFERON;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN METASTASIS; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS;

EID: 0030324563     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199611000-00008     Document Type: Article

References (32)

1. Fu KK, Phillips TL, Silverberg IJ, et al. Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J Clin Oncol 1987;5:1410-8.
2. Vogl SE, Schoenfeld DA, Kaplan BH, Lemer HJ, Engstrom PF, Horton JA. Randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer. Cancer 1985;56:432-42.
3. Stell PM, Dalby JE, Strickland P, Fraser JG, Bradley PJ, Flood LM. Sequential chemotherapy and radiotherapy in advanced head and neck cancer. Clin Radiol 1983;34:463-7.
4. Tannock IF, Browman G. Lack of evidence for a role of chemotherapy in the routine management of locally advanced head and neck cancer. J Clin Oncol 1986;4:1121-6.
5. Vlock DR, Schantz SP, Fisher SG, et al. Clinical correlates of circulating immune complexes and antibody reactivity in squamous cell carcinoma of the head and neck. J Clin Oncol 1993; 11: 2427-33.
6. Vlock DR. Immunobiological aspects of head and neck cancer: clinical and laboratory correlates. Hematol/Oncol Clin N Am 1991; 5:797-819.
7. Kirkwood JM, Emstoff MS. Interferons in the treatment of human cancer. J Clin Oncol 1984;2:336-52.
8. Kirkwood JM, Harris JE, Vera R et al. A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res 1985;45:863-71.
9. Medenica R, Slack N. Immunomodulatory activity of human leukocyte interferon in cancer patients: results obtained during pulse therapy schedule. Cancer Drug Delivery 1985;2:91-118.
10. Padovan I, Brodarec I, Ikic D, Knezevic M, Soos E. Effect of interferon in therapy of skin and head and neck tumors. J Cancer Res Clin Oncol 1981;100:295-310.
11. Medenica R, Slack N. Clinical results of leukocyte interferon induced tumor regression in resistant human metastatic cancer resistant to chemotherapy and/or radiotherapy-pulse therapy schedule. Cancer Drug Delivery 1985;2:53-76.
12. Connors JM, Andiman WA, Howarth CB, et al. Treatment of nasopharyngeal carcinoma with human leukocyte interferon. J Clin Oncol 1985;3:813-7.
13. Vlock DR, Johnson JT, Myers E, et al. Preliminary trial of non-recombinant interferon alpha in recurrent squamous cell carcinoma of the head and neck. Head Neck 1991;13:15-21.
14. Zelen M. The randomization and stratification of patients to clinical trials. Chron Dis 1974;27:365-75.
15. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
16. Whiteside TL, Letessier E, Hirabayashi H, et al. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res 1993;53:5654-62.
17. Nonparametrics: statistical methods based on ranks. San Francisco: Holden Day, 1975.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
19. Silver HK, Connors JM, Kong S, Karim KA, Spinelli JJ. Survival, response and immune effects in a prospectively randomized study of dose strategy for alpha-interferon. Br J Cancer 1988;58:763-7.
20. Pyrhonen S, Kouri M, Holsti LR, Cantell K. Disease stabilization by leukocyte alpha interferon and survival of patients with metastatic melanoma. Oncology 1992;49:22-6.
21. Smalley RV, Andersen JW, Hawkins MJ, et al. Interferon alfa combined with cytotoxic chemotherapy for patients with nonHodgkin’s lymphoma. N Engl J Med 1992;327:1336.
22. Bajetta E, Di Leo A, Zampino MG, et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alpha-2a in the treatment of advanced melanoma. J Clin Oncol 1994;12:806-11.
23. Ludwig H, Cohen AM, Huber H, et al. Interferon with VMCP compared to VMCP for induction and interferon compared to control for remission maintenance in multiple myeloma. Proc Am Soc Clin Oncol 1994; 13:1393.
24. Bowman GP, Rubin S, Walker I, et al. Interferona-2b maintenance therapy prolongs progression-free and overall survival in plasma cell myeloma: results of a randomized trial. Proc Am Soc Clin Oncol 1994; 13:1391.
25. Recondo G, Armand JP, Tellez-Bemal E, et al. Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy. Laryngoscope 1991;101:494-501.
26. Rowland KM, Taylor SG, Spiers ASD, et al. Cisplatin and 5-FU infusion chemotherapy in advanced, recurrent cancer of the head and neck: an Eastern Cooperative Oncology Group pilot study. Cancer Treat Rep 1986;70:461.
27. Schantz SP, Shillitoe EJ, Brown B, Campbell B. Natural killer cell activity and head and neck cancer: a clinical assessment. J Natl Cancer Inst 1986;77:869-75.
28. Schantz SP, Peters LJ. Patterns of recurrence from head and neck cancer: an immunologic perspective. Am J Clin Oncol 1987; 10: 469-74.
29. Schantz SP, Brown BW, Lira E, Taylor DL, Beddingfield N. Evidence for the role of natural immunity in the control of metastatic spread of head and neck cancer. Cancer Immunol Immunother 1987;25:141-8.
30. Racz T, Sacks PG, Taylor DL, Schantz SP. Natural killer cell lysis of head and neck cancer. Arch Otolaryngol Head Neck Surg 1989; 115:1322-8.
31. Wolf GT, Amendola BE, Diaz R, Lovett EJ, Hammerschmidt RM, Peterson KA. Definite vs adjuvant radiotherapy: comparative effects on lymphocyte populations in patients with head and neck squamous carcinoma. Arch Otolaryngol 1985;111:716-26.
32. Vlock DR, Kalish L, Crouse C, Dutcher J, Adams G. Phase II trial of interferon alpha and chemotherapy in locally recurrent or metastatic head and neck cancer: preliminary results of ECOG trial EST 1390. Proc Am Assoc Clin Oncol 1993; 12:918.